The QualityStocks Daily Wednesday, August 21st, 2024

Today's Top 3 Investment Newsletters

QualityStocks(GDC) $3.9200 +127.91%

Premium Stock Alerts(REVB) $2.0900 +101.27%

StockWireNews(GLMD) $0.4300 +42.43%

The QualityStocks Daily Stock List

GD Culture (GDC)

QualityStocks, INO Market Report, Prism MarketView, MarketClub Analysis and bullseyeoptiontrading reported earlier on GD Culture (GDC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GD Culture Group Limited (NASDAQ: GDC) is a holding firm that operates through its primary business conduit, AI Catalysis Corp.

The firm has its headquarters in Nevada and was incorporated in 2018, on February 6th. Prior to its name change in January 2023, the firm was known as Code Chain New Continent Ltd. It operates as part of the electronic gaming and multimedia industry, under the communication services sector. The firm serves consumers around the globe.

The company’s main businesses include AI-driven digital human technology; Live-streaming e-commerce; and Live streaming interactive games. Under its AI business division, it is focused on providing technology application services of digital human creation and customization for social media influencers or SMBs (Small and Medium-sized Businesses) in the consumer industry to help the clients optimize their online marketing and advertising. Under the e-commerce business, its focus is on capturing TikTok's popular trend by offering carefully selected product choices with smooth delivery, aiming to redefine the online shopping experience. It has formulated a dual strategy employing both short video and live streaming to afford online shoppers a more convenient and interactive shopping experience. On the other hand, the interactive game division is focused on diversifying its game offerings and the anchor personalities for TikTok users.

The firm, through its AI Catalysis subsidiary, announced recently that its portfolio company, DigiTrax Entertainment Inc. had unveiled a new AI Music Training Model License offered in its patented AI platform KR38R LAB’s Artist and Label Services. This move unlocks innovative AI-driven creative possibilities and may positively influence investments into the firm.

GD Culture (GDC), closed Wednesday's trading session at $3.92, up 127.907%, on 81,417,497 volume. The average volume for the last 3 months is 6.773M and the stock's 52-week low/high is $0.585175/$5.81.

Applied DNA Sciences (APDN)

Greenbackers, QualityStocks, MarketClub Analysis, OTCPicks, Free Hot Penny Stocks, StockMarketWatch, MarketBeat, Penny Stock Pick Alert, IRGnews Alert, Wall Street Resources, BUYINS.NET, The PennyStock Picks, Early Bird, Real Pennies, Standout Stocks, Schaeffer's, SuperNova Elite, Super Nova Stock Picks, TraderPower, StreetInsider, We Pick Penny Stocks, Liquid Tycoon, Stock Analyzer, Penny Stock MoneyTrain, StockEgg, Beacon Equity Research, Super Hot Penny Stocks, FeedBlitz, CoolPennyStocks, MicroStockProfit, HotOTC, OTCReporter, PennyStockScholar, Wall Street Grand, PennyTrader Publisher, PennyStockProphet, OTCtipReporter, Trades Of The Day, Top Stock Picks, Proactivecrg, Penny Stock Finder, INO Market Report, Penny Stock Solutions, Otcstockexchange, Penny Pick Finders, Penny Stock Chaser, Penny Performers, InvestorPlace, BullRally, INO.com Market Report, Dubai Penny Stocks, Marketbeat.com, Lebed.biz, HotPennyStocksNow, Investor Ideas, Micro Cap Pulse, Stock Rich, TradersPro, The Penny Play, Stockpalooza, StockOnion, StockHideout, Penny Stock Pick Report, SmallCapVoice, Profitable Trader Authority, PennyStockVille, PennyStocks24, PennyStockCrowd, PennyInvest, 24-7 Stock Alert, Penny stock-pick, Daily Trade Alert, HEROSTOCKS, StockRun, Streetwise Reports, The Online Investor, StockRich, DrStockPick, Daily Markets, Top Stock Tips, Buzz Stocks, Penny Stock Rumble, Trading Concepts, BoonMarket, Bloomfield Investment Club, Winning Penny Stock Picks, ThePUMPTracker, Stock Brain, PennyPic, OTC Stock Review, Monster Stock Alerts, Momentum Playerz, Premium Stock Alerts, MicrocapVoice, Penny Invest, Stockoutlaws, Stock Beast, Stock Marketing Inc., MadPennyStocks, Stock Gumshoe, Wise Alerts, Pennybuster, Stockhunter.us, Investing Futures, Penny Stock Explosion and PennyOmega reported earlier on Applied DNA Sciences (APDN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Applied DNA Sciences Inc. (NASDAQ: APDN) (FRA: UDJP) is focused on developing and marketing technology solutions which are DNA-based that can be used in the drug manufacturing and developing markets, as well as for anti-theft, anti-counterfeiting and supply chain security applications.

The firm has its headquarters in Stony Brook, New York and was incorporated in 1983. Prior to its name change in 2002, the firm was known as Datalink Systems Inc. It operates as part of the technology sector, under the technology hardware and semiconductors industry. The firm serves consumers in Asia, Europe and the U.S.

The company is focused on offering DNA-based authentication and security solutions and services which protect intellectual property, supply chains, brands, products and assets of consumers, governments and companies from diversion, fraud, counterfeiting and theft.

The enterprise’s product authentication and security solutions include its molecular tags under the SigNature brand, which offer forensic protection and power for different applications. They can be used to strengthen brand protection efforts. This is in addition to tracking and convicting criminals. It also produces the CertainT supply chain platform which offers proof of product claims for products, items or materials; and its SigNify portable DNA readers and consumable reagent test kits, which offer real-time molecular tags authentication.

The firm recently entered into an agreement with Flora Growth to deploy its CertainT platform as part of the latter company’s product validation and authentication platform for government regulators, distributors and consumers. The move will not only bring in additional revenue into the firm but also encourage more investments into the firm.

Applied DNA Sciences (APDN), closed Wednesday's trading session at $2.07, up 34.4156%, on 25,251,689 volume. The average volume for the last 3 months is 21,085 and the stock's 52-week low/high is $0.3131/$30.60.

One World Lithium (OWRDF)

We reported earlier on One World Lithium (OWRDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

One World Lithium Inc. (OTCQB: OWRDF) (CNSX: OWLI) is an exploration firm involved in acquiring, exploring for, and developing lithium resource properties and lithium separation extraction technology.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1982, on November 9th. Prior to its name change in January 2018, One World Lithium was known as One World Minerals Inc. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers primarily in Canada.

The company’s mission is to build commercial operating plants while also continuing its research and development programs for its lithium carbonation technology.

One World Lithium is focused on properties that contain lithium carbonate in brine and commercial application of the DOE's separation technology. The DOE patent is an advanced direct lithium extraction (DLE) process for the extraction of lithium from natural brines. It intends to license or joint venture its technology to current and future lithium carbonate producers and consumers. The enterprise’s technology has the potential to change the lithium extraction industry, with its patent applications being allocated for natural brine and for slurries made from pegmatite, clay, volcanic rock and sediment.

The firm, which is party to a definitive agreement with MatterGreen LLC involving the assignment of 2 separate patent applications for lithium carbonation, recently completed the first tranche of its non-brokered private placement. It remains focused on properties that may contain lithium while also creating additional value for its shareholders.

One World Lithium (OWRDF), closed Wednesday's trading session at $0.0263, even for the day. The average volume for the last 3 months is 95.089M and the stock's 52-week low/high is $0.012/$0.0388.

Tesla Inc. (TSLA)

The Street, Green Car Stocks, InvestorPlace, StreetInsider, Schaeffer's, Kiplinger Today, Investopedia, Zacks, MarketClub Analysis, MarketBeat, The Online Investor, Daily Trade Alert, Money Morning, Options Elite, StreetAuthority Daily, Trades Of The Day, Early Bird, Market Intelligence Center Alert, Cabot Wealth, Energy and Capital, All about trends, StocksEarning, Wealth Daily, CNBC Breaking News, TopStockAnalysts, InvestorGuide, Uncommon Wisdom, Barchart, StockEarnings, The Motley Fool, Louis Navellier, Street Insider, MarketWatch, Daily Profit, Profit Confidential, Trading Tips, AllPennyStocks, Marketbeat.com, Money and Markets, Top Pros' Top Picks, ProfitableTrading, Investors Alley, InvestorIntel, Alternative Energy, Money Wealth Matters, SmarTrend Newsletters, TipRanks, INO Market Report, Wyatt Investment Research, Wealth Insider Alert, StrategicTechInvestor, Investor Guide, Wall Street Daily, The Wealth Report, Investing Daily, FreeRealTime, Greenbackers, Investment U, CustomerService, Market Intelligence Center, smartmoneytrading, QualityStocks, The Street Report, MarketTamer, Stock Up Featured, INO.com Market Report, Wall Street Elite, Daily Wealth, Trading Concepts, Hit and Run Candle Sticks, wyatt research newsletter, Eagle Financial Publications, National Inflation Association, The Growth Stock Wire, Investiv, SureMoney, Jon Markman’s Pivotal Point, DividendStocks, StockMarketWatch, Wall Street Profit Search, GorillaTrades, Investing Futures, Short Term Wealth, Market Authority, Streetwise Reports, Insider Wealth Alert, Darwin Investing Network, Total Wealth, Stock Barometer, Investment House, equities Canada, Dynamic Wealth Report, SmallCapVoice, SmallCap Network, Rick Saddler, Chaikin PowerFeed, Bourbon and Bayonets, Average Joe Options, Rockwell Trading, Inside Investing Daily, Equities.com, The Stock Dork, TheStockAdvisors, Stock Gumshoe, The Night Owl, Dividend Opportunities, WStreet Market Commentary, The Best Newsletters, Investor News, InvestorsUnderground, Prism MarketView, The Trading Report, Daily Dividends, Lance Ippolito, Trade of the Week, FeedBlitz, Power Profit Trades, Outsider Club, Lebed.biz, BUYINS.NET, BillionDollarClub, OilAndEnergyInvestor, Wall St. Warrior, Shah's Insights & Indictments, TheOptionSpecialist, Direction Alerts, Tim Bohen, InvestorsObserver Team, Stock Tips Network, TradersPro, Contrarian Outlook, 360wallstreet, Investor Ideas, 777 Stocks, Economic News Room, GreenCarStocks, InvestmentHouse, bullseyeoptiontrading, Market Trends, Investors Underground, Market FN, Jason Bond, InsiderTrades, BullDogReporter, Smart Investing Society, The Wall Street Transcript, Terry's Tips, Trader Prep, TradeSmith Daily, TradingPub, The Weekly Options Trader, Stock Analyzer, SmallCapNetwork, Visual Capitalist, Senior Resource, Schaeffer’s, Wall Street Window and Wealthpire Inc. reported earlier on Tesla Inc. (TSLA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Several states in America are scrambling to replace gasoline taxes as more and more of their residents replace their internal combustion engine (ICE) vehicles with electric vehicles. This has resulted in situations where states pass levies or taxes on people who purchase battery electric vehicles (BEVs) that some stakeholders referred to as penalties for purchasing an EV. Ironically, many of these states offered their residents EV subsidies before deciding to slap them with a tax for EV ownership.

Those who support these electric vehicle taxes say they are needed to replace the gasoline taxes states would use to maintain their roads. With electric vehicle adoption rising across the country, several states have seen a notable fall in the revenue they used to earn from petrol and diesel taxes. These gasoline taxes could eventually become obsolete as America pursues total electrification over the next couple of decades.

Pennsylvania, for instance, charges the second-highest tax on gasoline in the U.S., meaning the state misses out on significant revenue every time an EV driver skips a gas station to refill their vehicle at a public charging station. Fearing a future where Pennsylvania derives little to no tax revenue from its fleet of vehicles, state lawmakers overwhelmingly approved a measure to impose an electric vehicle fee.

According to the chair of the House Transportation Committee and Democratic state Rep. Ed Neilson, the electric vehicle levy would ensure that EVs ‘pay their fair share.’ At the moment, Neilson says, non-electric vehicle drivers are paying for electric vehicle drivers to use the roads. Once the $250 yearly electric vehicle fee takes effect, Pennsylvania will have one of the highest EV fees in the U.S.

At least 36 states have adopted similar fees on BEVs and hybrid electric cars to make up for the revenue gap caused by falling gasoline taxes, with some rolling back additional EV-related incentives and others reworking their policies to make electric vehicle owners pay higher registration fees. In most cases, both Democratic and Republican lawmakers have offered their support for these fees even though they increase the cost of EV ownership to help bridge budgetary shortfalls.

After compiling gasoline tax data from all states, PEW Charitable Trusts found that the gasoline tax revenue in some states has fallen even lower than the levels seen during Bill Clinton and even George W. Bush administrations. With the tax acting as America’s transport funding backbone for the past several decades, states will now have to figure out alternative models of funding to ensure they have enough tax revenue to maintain their roads and keep them running as effectively as possible.

EV makers, such as Tesla Inc. (NASDAQ: TSLA), now have to contend with these headwinds presented by local and state government tax policies which will in most cases be perceived as inflating the cost of owning an EV, and many buyers are likely to hesitate to make the switch due to these added costs.

Tesla Inc. (TSLA), closed Wednesday's trading session at $223.27, up 0.9814563%, on 70,145,964 volume. The average volume for the last 3 months is 14.777M and the stock's 52-week low/high is $138.8025/$278.98.

Core Scientific (CORZ)

Schaeffer's, MarketBeat, MarketClub Analysis, Trades Of The Day, The Stock Dork, QualityStocks, Premium Stock Alerts, InsiderTrades, Eagle Financial Publications, Daily Trade Alert and 360 Wall Street reported earlier on Core Scientific (CORZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Core Scientific (NASDAQ: CORZ), a leader in digital infrastructure for bitcoin mining and high-performance computing, has repaid a total of $267 million in debt with proceeds from its recently closed convertible senior notes issue. According to the announcement, the company repaid $150 million in secured notes, $61 million in an exit facility and $56 million in miner equipment loans, in addition to interest and other fees. The repayment reduced interest rates from approximately 12.5% to 3%.

The announcement noted that the convertible notes offering raised net proceeds of $172.8 million after all payments (including commissions and estimated offering expenses), significantly increasing cash on hand to fund site acquisitions for HPC hosting growth and other growth initiatives and strengthen its bitcoin mining business. “Our recent convertible note issue represents another key step in our commitment to strengthen our balance sheet and position Core Scientific for future growth,” said Adam Sullivan, Core Scientific’s CEO.

To view the full press release, visit https://ibn.fm/TkE8N

About Core Scientific, Inc.

Core Scientific is a leader in digital infrastructure for bitcoin mining and high-performance computing. The company operates dedicated, purpose-built facilities for digital asset mining and is a premier provider of digital infrastructure, software solutions and services to its third-party customers. Core Scientific employs its own large fleet of computers (“miners”) to earn bitcoin for its own account and provide hosting services for large bitcoin mining and high-performance computing customers at its eight operational data centers in Georgia (2), Kentucky (1), North Carolina (1), North Dakota (1) and Texas (3). The company derives the majority of its revenue from earning bitcoin for its own account (“self-mining”). For more information about the company, visit www.corescientific.com.

Core Scientific (CORZ), closed Wednesday's trading session at $10.54, up 3.9448%, on 11,108,041 volume. The average volume for the last 3 months is 22.283M and the stock's 52-week low/high is $2.61/$12.25.

Snap, Inc. (SNAP)

Schaeffer's, InvestorPlace, The Street, MarketClub Analysis, MarketBeat, StockEarnings, StocksEarning, Trades Of The Day, Kiplinger Today, Zacks, StreetInsider, Daily Trade Alert, Market Intelligence Center Alert, INO Market Report, The Online Investor, Investopedia, Wealth Insider Alert, CNBC Breaking News, Early Bird, Barchart, The Street Report, QualityStocks, Marketbeat.com, StockMarketWatch, Trading Concepts, StreetAuthority Daily, Profit Confidential, Louis Navellier, Top Pros' Top Picks, Market Intelligence Center, FreeRealTime, AllPennyStocks, Investors Alley, GorillaTrades, Daily Profit, Money Morning, Jon Markman’s Pivotal Point, TopStockAnalysts, Investment House, InvestmentHouse, Uncommon Wisdom, Total Wealth, Cabot Wealth, Trading Tips, 24/7 Trader, The Wealth Report, TipRanks, MarketTamer, Investiv, Investing Daily, Investment U, MarketWatch, Max Wealth, Energy & Resources Digest, Economy & Markets, Dynamic Wealth Report, Rick Saddler, SmallCap Network, StockGuru, Wall Street Window, wyatt research newsletter, Daily Wealth, Epic Stock Picks, Direction Alerts, BUYINS.NET, 360 Wall Street, Premium Stock Alerts, Wealth Week, Wealth Daily, Wall Street Profit Search, Wall Street Daily, Technology Profits Daily, StrategicTechInvestor, StockRockandRoll, Schaeffer’s, Promotion Stock Secrets, newmoneycrew, Prism MarketView, InvestorsObserver Team, Power Profit Trades, PennyStockLocks, Penny Stock 101, Penny Picks, OTC Stock Review, Money and Markets, MarketClub, Jon Markman's Pivotal Point, InvestorsUnderground and ProfitableTrading reported earlier on Snap, Inc. (SNAP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Snap (NYSE: SNAP), the parent company behind the popular social media platform Snapchat, is making waves with its innovative approach to enhancing user engagement and deepening community connections. With a recent announcement of reaching 850 million monthly active users in the second quarter and over 11 million subscribers to Snapchat+, Snap is on a clear path to achieving its ambitious goal of 1 billion monthly users. This growth is underpinned by a series of new features and improvements aimed at making communication more expressive and engaging.

The introduction of Map Reactions, Editable Chats, and My AI Reminders are just a few examples of how Snap is revolutionizing the way users interact on the platform. These updates not only make the app more user-friendly but also significantly contribute to the daily active user growth. By focusing on making communication more expressive, Snap is ensuring that users have a more personalized and engaging experience, which is crucial for retaining and attracting new users.

Snap’s efforts in improving user experience have led to all-time highs in daily active users sending Snaps across every region, showcasing the effectiveness of their strategy. The company’s focus on content, highlighted by a 25% year-over-year increase in global time spent watching content, is driving significant engagement. This is further supported by the popularity of Spotlight and Creator Stories, which have seen a 10% quarter-over-quarter growth. The growing content ecosystem, evidenced by a 20% year-over-year increase in the number of creators submitting Spotlight content, underscores Snap’s commitment to fostering a vibrant community of creators.

The partnership with Live Nation and the introduction of Snap Nation, along with the investment in machine learning and generative artificial intelligence for content ranking and personalization, demonstrate Snap’s innovative approach to enhancing user engagement. The focus on augmented reality (AR), with a 12% year-over-year increase in the number of Snapchatters sharing AR Lens experiences, is setting new standards in the industry. Noteworthy AR innovations, such as the ML Scribble World Lens and the generative AI Lens launched in collaboration with Beyoncé, have achieved remarkable engagement, showcasing the potential of AR in enriching user interactions.

Despite the slight decrease in its stock price to $9.44, experiencing a minor drop of $0.03 or -0.27%, Snap Inc. remains a formidable player in the social media space. With a market capitalization of approximately $15.5 billion and a trading volume of 4.66 million shares on the NYSE, Snap’s financial health and innovative strategies position it well for future growth. The company’s focus on enhancing the performance of its iOS app, through improvements in battery management, app and screen loading times, and camera quality, further illustrates its commitment to providing a superior user experience.

To view the company’s most recent earnings release, visit https://ibn.fm/wwfD1

About Snap Inc.

Snap Inc. is a technology company. We believe the camera presents the greatest opportunity to improve the way people live and communicate. We contribute to human progress by empowering people to express themselves, live in the moment, learn about the world, and have fun together. For more information, visit the company’s website at www.Snap.com.

Snap, Inc. (SNAP), closed Wednesday's trading session at $9.48, up 0.1055966%, on 17,946,341 volume. The average volume for the last 3 months is 6.567M and the stock's 52-week low/high is $8.28/$17.90.

GeoVax Labs (GOVX)

Wall Street Resources, QualityStocks, IRGnews Alert, Standout Stocks, MarketClub Analysis, MarketBeat, Premium Stock Alerts, SmallCapVoice, Penny Performers, BUYINS.NET, InvestorPlace, SmallCapStockPlays, Stock News Now, Stock Stars, Stockpalooza, HotOTC, FeedBlitz, M2 Communications, DrStockPick, Daily Market Beat, CoolPennyStocks, INO Market Report, Money Wealth Matters, PennyOmega, PoliticsAndMyPortfolio, Prism MarketView, ProActive Capital, Schaeffer's, The Online Investor, The Street, Timothy Sykes, TradersPro, Wall Street Mover and PennyTrader.com reported earlier on GeoVax Labs (GOVX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GeoVax Labs (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, has entered into a definitive securities purchase agreement with a certain institutional investor. The agreement is for the purchase and sale of 1,700,000 shares of the company’s common stock (or common stock equivalents), offered at $5 per share as part of a registered direct offering. The company will also issue the investor(s), in a concurrent private placement, warrants to purchase up to 1,700,000 shares of common stock. The exercise price of the warrants is also $5 per share. The warrants will be exercisable immediately following the date of issuance and will expire five years from being issued. Roth Capital Partners is the exclusive placement agent for the offering.

To view the full press release, visit https://ibn.fm/OE8jV

About GeoVax Labs Inc.

GeoVax is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation, COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; (2) a booster vaccine in patients with chronic lymphocytic leukemia (“CLL”); and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), in a multicenter phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The company has a leadership team that have driven significant value creation across multiple life science companies over the past several decades. To learn more about the company, visit www.GeoVax.com.

GeoVax Labs (GOVX), closed Wednesday's trading session at $8.35, up 47.007%, on 21,570,157 volume. The average volume for the last 3 months is 406,482 and the stock's 52-week low/high is $1.0901/$11.18.

Verano Holdings Corp. (VRNOF)

QualityStocks, MarketBeat, InvestorPlace, CannabisNewsWire, The Street, Earnings360, Early Bird and Cabot Wealth reported earlier on Verano Holdings Corp. (VRNOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

As of last week, medical cannabis was legal in Ukraine. This comes about half a year after President Volodymyr Zelensky signed the medical marijuana bill into law, making access to these drugs easier so soldiers could address the mental and physical wounds incurred during the country’s ongoing war with Russia, which invaded Ukraine more than two years ago.

In an update on the new policy, the Ministry of Health stated that marijuana, along with its extracts, resin and tinctures, were excluded from the list of possibly dangerous substances.

Prior to this, the drug’s circulation was banned, but now it’s permitted with some restrictions. Licensing regulations that ensure the cultivation of medical marijuana in Ukraine have been developed and will soon be considered by the Cabinet.

It is important to note that the drug’s chain of circulation, from cultivation or import to dispensing the drug will be subject to license control.

In a post on Facebook, the ministry added that this was a huge step forward in offering care to patients in need of certain treatments. Ukraine had already begun importing cannabis products since the drug was moved to List II of the nation’s drug code, easing access for medical use with a prescription.

While legislators passed the medical marijuana bill in December 2023, the Batkivshchyna party tried to block it by forcing consideration of a legislation to revoke the bill. That legislation failed earlier this year, clearing the bill’s path to enactment. The opposition had also tried to derail the cannabis bill by filing hundreds of amendments. This had also failed, however, with the bill being approved by 248 votes.

The legislation’s taking effect will legalize medical marijuana for patients with post traumatic stress disorder (PTSD) and other serious illnesses that have resulted from the country’s ongoing conflict with Russia. While the legislation stipulates that medical marijuana may only be dispensed to patients with cancer and warborne PTSD, the health committee’s chair stated in July that legislators heard daily from patients with illnesses such as epilepsy and Alzheimer’s disease.

The National Police and State Agency on Medicines will hold enforcement and oversight authorities associated with the distribution of the drug. The Ministry of Agrarian Policy is also expected to hold regulatory responsibilities over marijuana growing and processing operations.

In an interview, the country’s deputy prime minister for European and Euro-Atlantic Integration, Olha Stefanishyna, stated that patients would first have access to imported drugs. She explained that where the drugs came from would depend on foreign manufacturers that possessed the required documents and were approved at the registration stage.

The list of approved conditions that make patients eligible to access medical marijuana shall be published in the coming days.

The coming into force of the medical cannabis law could create a window of opportunity for some established entities, such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF), in case they pick an interest in growing their footprint into this international market.

Verano Holdings Corp. (VRNOF), closed Wednesday's trading session at $3.94, up 0.5102041%, on 71,536 volume. The average volume for the last 3 months is 75,203 and the stock's 52-week low/high is $2.53/$7.08.

Bit Mining Ltd. (BTCM)

QualityStocks, MarketClub Analysis, StockEarnings, Schaeffer's, CryptoCurrencyWire, Wall St. Warrior, The Stock Dork, StocksEarning, smartmoneytrading, MarketBeat, INO Market Report, FreeRealTime and 247 Market News reported earlier on Bit Mining Ltd. (BTCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Former President Donald Trump holds more than $1 million in crypto assets and has profited $300,000 from selling branded Bibles, according to a recent personal financial disclosure. The branded Bible, named the Greenwood Bible, is priced at $59.99.

According to the product’s website, it includes a handwritten chorus from the patriotic hymn “God Bless the U.S.” performed by country musician Lee Greenwood. There is also a limited edition available for $1,000 with Trump’s signature.

In addition to a cryptocurrency wallet, Trump owns virtual Ether key holdings worth $1 million to $5 million according to the disclosure.

His position on cryptocurrencies has noticeably changed since his early days in office when he first said digital currencies were fake. Over time, Trump has adopted a more lenient stance toward cryptocurrency; as part of his campaign plan, he even advocated for the creation of a “cryptocurrency army.”

This change in perspective appears to be impacted by the industry’s lobbying efforts as well as an awareness of the popularity of cryptocurrencies among some of Trump’s fans. The majority of this population consists of young people who participate in online communities.

During a livestream with content creator Adin Ross, Trump mentioned that he knows a lot of “good people” who work in the crypto space and described them as intelligent and progressive. He also issued a warning, saying China would lead the crypto business if the United States did not participate in it.

Trump estimated the worth of his social media business, Truth Social, to be between $5 million and $25 million in a prior financial statement. This year, he revealed a substantially larger valuation — more than $50 million — for the business known as Trump Media and Technology Group Corporation. Furthermore, his financial filings indicate a notable increase in the number of Chinese trademark registrations. Trump disclosed only two trademarks in China last year; however, NBC News’ review of his 2024 filing shows that this number has since increased to more than 100.

After officially declaring candidacy, federal regulations require officeholders and candidates to submit yearly financial disclosures. These filings typically outline broad details about incomes, assets and investments.

JD Vance, Trump’s running mate, also has significant cryptocurrency holdings, reportedly valued between $100,000 and $250,000, stored on the Coinbase exchange. Vance, the author of Hillbilly Elegy, has emerged as a strong advocate for crypto, viewing it as a viable alternative to traditional financial systems. He has expressed his support for crypto in combating government overreach, referencing the action taken by the Canadian finance minister to freeze some truckers’ bank accounts because they were opposed to COVID-19 lockdown measures.

The revelation that prominent people such as Trump have substantial crypto holdings is further testament to industry players such as Bit Mining Ltd. (NYSE: BTCM) that cryptocurrencies are becoming entrenched in major markets and there is no turning back for the industry.

Bit Mining Ltd. (BTCM), closed Wednesday's trading session at $2.34, up 6.8493%, on 61,148 volume. The average volume for the last 3 months is 590,319 and the stock's 52-week low/high is $1.79/$6.95.

Cresco Labs Inc. (CRLBF)

QualityStocks, InvestorPlace, Kiplinger Today, Daily Trade Alert, MarketBeat, Cabot Wealth, Top Pros' Top Picks, The Street, CannabisNewsWire, The Wealth Report, Wealth Insider Alert, Trading For Keeps, Trades Of The Day, The Online Investor, Early Bird, Prism MarketView, StreetInsider, wyatt research newsletter, TradersPro and StocksEarning reported earlier on Cresco Labs Inc. (CRLBF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cannabis corporations are spending more than ever to sway lawmakers in Congress, as evidenced by a federal lobbying report analysis. This expenditure is motivated by the first real steps toward federal marijuana legalization in a generation as well as threats from competitors using hemp as a raw material.

Marijuana companies spent nearly $4 million in the first and second quarters of 2024, a significant increase from $2.4 million in 2023. This surge in spending mirrors a similar uptick in late 2022, when cannabis banking reform seemed imminent during a congressional session. The current rise, however, is more significant because it takes into account the larger range of legislation that is being considered, such as the farm bill and the Biden administration’s efforts to reschedule cannabis, which may lessen the restrictions imposed by Section 280E.

Charlie Panfil, a prominent lobbyist with the Daschle Group, a public policy agency based in Washington, DC, says there is increasing awareness that marijuana reform is becoming a more bipartisan subject.

While the spending data show the resources being used to influence politicians at the federal level, the data does not fully convey the scope of the endeavors. Significant time and effort is also devoted to cannabis-related problems by powerful political players with strong interests in marijuana, such as the beer behemoth Anheuser-Busch and the tobacco company Altria Client Services. However, lobbying reports do not completely reflect this.

A wide range of entities have been interacting with Congress on cannabis-related issues during the past year. These include large insurance corporations, financial unions, and lobbyists for state and municipal government agencies.

Despite these efforts, the impact remains uncertain. It is unlikely that the current Congress will adjourn with any major advancements toward a new farm bill or banking reform. This may indicate that the legal loophole allowing the online sale of intoxicating hemp-derived goods in the majority of the United States will remain in place.

Furthermore, the U.S. Department of Justice’s rescheduling procedure is largely outside the purview of Congress, and Section 280E will stay in force until the process is completed, a procedure that is unlikely to be influenced by lobbyists.

Advocacy groups and individual marijuana multistate operators (MSOs) in Washington, DC, continue to have a substantial amount of spending power. For instance, Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), an MSO based in Chicago, has invested $1.24 million this year for internal lobbyists and to keep the services of significant government relations companies such as Brownstein Hyatt Farber Schreck, which also represents credit unions in congressional lobbying on marijuana banking. Compared to the $250,000 the company spent in the first half of 2023, this is a significant rise.

Curaleaf Holdings also spends $290,000 every quarter on lobbying. Of that amount, $80,000 goes to Brownstein Hyatt Farber Schreck, $140,000 goes to its in-house lobbyist and $70,000 goes to Cozen O’Connor Public Strategies, an advisory company.

In some instances, the spending by cannabis companies rivals that of major companies. For instance, the $80,000 that Cresco Labs paid to Brownstein Hyatt Farber Schreck is the same amount that McDonald’s paid to Brownstein Hyatt Farber Schreck during the same period.

The additional challenges that cannabis companies encounter as a result of federal cannabis regulation are also highlighted by the companies’ higher spending. This might encourage legislators to delay resolving these difficulties because cannabis companies will have to keep paying for lobbying services for a longer period if these concerns remain, according to some observers.

Cresco Labs Inc. (CRLBF), closed Wednesday's trading session at $1.818, up 2.7119%, on 269,893 volume. The average volume for the last 3 months is 535,937 and the stock's 52-week low/high is $1.01/$2.77.

Oragenics (OGEN)

RedChip, StockMarketWatch, BUYINS.NET, QualityStocks, MarketBeat, StocksEarning, TopPennyStockMovers, FreeRealTime, StockOodles, The Street, The Stock Dork, Streetwise Reports, StreetAuthority Daily, Wall Street Mover, MarketClub Analysis, InvestorPlace and Investopedia reported earlier on Oragenics (OGEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has completed its spray-dried formulation and filling of the nasal device for its lead candidate, ONP-002, for the treatment of concussion. A new chemical entity, ONP-002 targets the brain through delivery into the nasal cavity. According to the announcement, the prefilled formulation will be used to provide dosing for the upcoming phase 2a clinical trial in concussed patients.

“In preparing for the phase 2a study, we wanted to ensure that ONP-002 could be formulated as a nanoparticle and delivered intranasally as a powder to improve brain exposure,” said Oragenics president Michael Redmond in the press release. “The anti-inflammatory effects of our novel neurosteroid are designed to reduce negative outcomes after a concussion. We believe the combination of the spray-dried powder in our device is ideal for field delivery, increasing the chances of stopping the neuropathology of a concussive injury early.”

To view the full press release, visit https://ibn.fm/Nxool

About Oragenics Inc.

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in fighting infectious diseases and neurological conditions, including drug candidates for treating mild traumatic brain injury, also known as concussion, and for treating Niemann Pick Disease Type C (“NPC”), as well as proprietary powder formulation and an intranasal delivery device. For more information about the company, please visit www.Oragenics.com.

Oragenics (OGEN), closed Wednesday's trading session at $0.944, up 1.4508%, on 2,103,732 volume. The average volume for the last 3 months is 205,582 and the stock's 52-week low/high is $0.8611/$7.74.

reAlpha Tech (AIRE)

QualityStocks, InvestorsUnderground and 360 Wall Street reported earlier on reAlpha Tech (AIRE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

reAlpha Tech (NASDAQ: AIRE), a real estate technology company developing and commercializing artificial intelligence (“AI”) technologies, has launched reAlpha. According to the announcement, the Super App is designed to bring an end-to-end, commission-free, real estate experience to users’ mobile devices. The company noted that the Super App is an addition to its online platform, combining Claire, reAlpha’s generative-AI buyer’s agent with licensed human-agent support and a suite of homebuying tools, such as title and escrow agent services.

As part of the launch, the name of the Super App was changed from Claire to reAlpha, although Claire will remain as the generative-AI buyer’s agent integrated within the Super App. Features of the Super App include commission-free homebuying; AI-generated search and recommendations; and AI document review and analysis. The Super App also provides expert guidance and end-to-end transactions.

“At reAlpha, we know buying a home is the biggest and most important decision many people will ever make,” said reAlpha president and COO Mike Logozzo in the press release. “We believe in leveraging AI to create a more personalized and supportive homebuying experience. reAlpha Super App is designed to provide homebuyers with all the tools and support they may need to find their dream home, at a great price and with the best experience, all from their mobile device.”

To view the full press release, visit https://ibn.fm/wkVw6

About reAlpha Tech Corp.

reAlpha Tech is a real estate technology company developing an end-to-end commission-free homebuying platform. Utilizing the power of AI and an acquisition-led growth strategy, reAlpha’s goal is to offer a more affordable, streamlined experience for those on the journey to homeownership. For more information about the company, please visit www.reAlpha.com.

reAlpha Tech (AIRE), closed Wednesday's trading session at $1.24, up 0.8130081%, on 41,084 volume. The average volume for the last 3 months is 1.074M and the stock's 52-week low/high is $0.5311/$575.41.

The QualityStocks Company Corner

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology ("I&I") biological products and on providing contract development and manufacturing organization ("CDMO") services through its Scinai Bioservices business unit, has closed on its previously announced loan restructuring agreement. According to the announcement, the agreement is with the European Investment Bank ("EIB") and includes an amendment.

Specifically, the agreement notes that "in connection with the transaction, an amount equal to approximately EUR 26.6 million (equal to approximately $29 million), including interest accrued to date, owed by the company to the EIB under the finance contract was converted into 1,000 preferred shares, no par value per share, of the company. Following such conversion, the total outstanding amount owed by the company to the EIB is EUR 250,000 (equal to approximately $273,000 ). The outstanding amount has a maturity date of Dec. 31, 2031, is not prepayable in advance, and no interest accrues or is due and payable on such amount."

To view the full press release, visit https://ibn.fm/RjIRn

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Wednesday's trading session at $4.3656, up 4.6906%, on 41,284 volume. The average volume for the last 3 months is 212,367 and the stock's 52-week low/high is $2.23/$13.90.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced receipt of blood glucose results from weeks 4 and 8 of its ongoing animal study WEIGHT-A24-1. The study is underway using diabetic, pre-conditioned Zucker rats. The results showed that DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A and B) were the top performers in the study at day 56, reducing blood sugar levels by 2.50%, 1.90% and 1.53% respectively. These results appear to support Lexaria's belief that DehydraTECH-CBD may have utility, particularly if used together with a GLP-1 drug, in diabetic control.

Additionally, select DehydraTECH-CBD formulations showed apparent superiority to DehydraTECH-GLP-1 at 4 and 8 weeks, while DehydraTECH-liraglutide showed apparent superiority to DehydraTECH-semaglutide. Animal testing of the combination of DehydraTECH-CBD with DehydraTECH-GLP-1 drugs is ongoing and in the final phases of the study, with additional results expected soon.

To view the full press release, visit https://ibn.fm/NW1YF

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $3.29, up 1.2308%, on 376,118 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $13.90/$.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

The company reported a 28% increase in revenue, a 6% rise in bookings, a 97% improvement in GAAP gross profit and a 444% increase in cash, for the second quarter of 2024, on a year over year basis

D-Wave's CEO, Dr. Alan Baratz, summarized the company's ongoing strategic direction and provided an expansive list of achievements

Highlights mentioned include a quantum AI product development roadmap extending D-Wave's Leap(TM) quantum cloud service, an expanded partnership with Zapata AI, new customer hybrid quantum applications, and more

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the first commercial provider of quantum computers, released its second quarter 2024 financial results along with recent business and technical updates. The company reported growth in key areas, reflecting its continued momentum in the quantum computing market (https://ibn.fm/DNZ11).

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Wednesday's trading session at $1.07, up 12.7384%, on 6,884,460 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.57/$2.44.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, today announced that Bollinger Motors, its subsidiary, intends to begin production of saleable units of the Bollinger B4 Chassis Cab, an all-new Class 4 commercial EV truck, on September 16, 2024. Bollinger Motors is partnering on production with Roush Industries, which provides contract manufacturing services from its facility in Livonia, Michigan. According to the announcement, deliveries and revenue recognition of the B4 EV truck is expected to begin in October 2024.

"We are already experiencing strong momentum in the market from important customers throughout the country," commented Jim Connelly, chief revenue officer of Bollinger Motors. "We are confident that we are bringing them a truck that will reward their trust and help transform their business. We cannot wait to get the B4 on the road, electrifying America's fleets."

To view the full press release, visit https://ibn.fm/Nvn9U

A new Rockefeller Foundation report has revealed that the world is facing a major green-energy gap that could potentially prevent it from achieving established renewable-energy goals. The findings point to a massive green power gap that's nearly two times larger than America's annual renewables capacity and underscored the pressing need for green energy in 72 nations. According to the Rockefeller Foundation's report, 72 countries in Asia, Africa, the Middle East, Latin America and the Middle East face an 8,700 terawatt-hour (TWh) renewable energy gap. The report states that this significant energy gap currently affects a whopping 3.8 billion people worldwide, making it a major barrier to the goal of achieving global carbon neutrality and eliminating greenhouse gas emissions. Deepali Khanna, Rockefeller Foundation vice president and head of the Asia Regional Office, notes that achieving a future of abundant clean energy won't be possible with a "one-size-fits-all" solution. Asia has a lot of potential because it has plenty of green-energy resources and already existing energy system assets. For instance, Khanna explained, Indonesia and India have already taken significant steps to increase their capacity for renewables and are now deploying green-energy technologies at an unprecedented scale and rate. What is reassuring is that the issue of climate change is being tackled using different approaches, such as phasing out vehicles powered by fossil fuels in favor of electric vehicles from thousands of global manufacturers, such as Mullen Automotive Inc. (NASDAQ: MULN), that are selling EVs with zero emissions at the tailpipe.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $0.2535, up 4.5361%, on 77,453,075 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.23/$96.00.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

Last week, Virginia's attorney general released an advisory opinion directing the Virginia retirement system in the state against making investment decisions that prioritized environmental, social and governance (ESG) issues. The attorney general, Jason Miyares, explained in the nonbinding legal analysis that the state's retirement system needed to base its investments on what would generate the best financial results for its beneficiaries. Members of the state's retirement systems include public school teachers, state employees and employees of political subdivisions, such as cities, towns and counties. This recent opinion was the AG's 10th opinion memo this year and was penned at the request of GOP's Delegate Nick Freitas, a member of the state's House of Delegates. As per the law, the AG shall give his advice and offer official advisory opinions in writing only when requested by the governor, a judge, a member of the General Assembly, a county or city sheriff, the state's Corporation Commission, or a county or city treasurer, among others. Despite these developments pushing back against ESG, there are many companies, such as Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF), that are embracing these principles and finding ways to incorporate them into every layer of their operations.

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.

Projects

Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Wednesday's trading session at $0.03355, up 11.8333%, on 7,800 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.03/$0.2336.

Recent News

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF)

The QualityStocks Daily Newsletter would like to spotlightFathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF).

Indonesia is an international hub for critical mineral production and reserves, with diverse resources including nickel, iron, bauxite, silver, tin, gold and copper. The country's mining industry has extensive nickel reserves in the Maluku, Sulawesi and Kalimantan islands. Nickel mined in the country is suitable for the production of electric car and stainless-steel batteries. During last year's ASEAN Summit, U.S. Vice President Kamala Harris and Indonesian President Joko Widodo discussed the potential of a critical minerals free-trade agreement. Diversifying investments would help Indonesia decrease the monopolistic influence of Chinese companies while also creating a fairer and competitive market environment, fostering better environmental and labor practices. These internal challenges plaguing the Indonesian nickel industry build a strong case for North American-based exploration companies such as Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) that are in jurisdictions where the highest standards regarding human rights, ethics and environmental consciousness are enforced. Supplies from these regions could soon dominate the Western market in lieu of materials from regions dominated by Chinese companies.

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is a Canadian natural resource development and exploration company that targets high-grade nickel sulfide discoveries for use in the rapidly growing global electric vehicle (EV) market. The company has a portfolio of two high-quality exploration projects located in the prolific Trans Hudson Corridor in Saskatchewan.

Led by a management team with more than 100 years of combined mining and exploration experience, Fathom believes in a continuing bright outlook for nickel and its increasing use in the manufacturing of batteries needed for energy storage in the high-growth renewable energy and EV industries. The company’s modern approach to exploration has yielded significant new nickel discoveries.

Fathom is headquartered in Calgary, Alberta.

Projects

The Albert Lake Project

The Albert Lake Project comprises 90,460 hectares of lands located in north-central Saskatchewan, with over 80,000 hectares currently unexplored. The project is host to the historic Rottenstone Mine, a high-grade, open pit nickel sulfide past producer that was active from 1965 to 1969 and yielded ~26,000 tonnes of 3.3% Ni, 1.8% Cu, and >9 g/t Pd-Pt+Au.

The geological setting of the Albert Lake Project is within the Trans Hudson Orogeny (Corridor), which is host to numerous world-class nickel mining camps including the Thompson Nickel Belt (currently operating with more than 5 billion pounds of nickel produced since 1959), Lynn Lake (past producer) and Raglan Nickel Belt (currently operating with more than 39,000 tons of nickel produced in 2020).

The project is fully permitted. Exploration plans for 2024 include drilling a high-priority target located approximately 2km south of the historic Rottenstone Mine along with drilling other high-priority targets. Additional soil geochemistry, surface geophysical programs and geological mapping and prospecting will be performed during the summer field season.

The Gochager Lake Project

The Gochager Lake Project in northern Saskatchewan, also in the prolific Trans Hudson Corridor, was recently expanded through the addition of the contiguous Watt’s Lake property and direct staking, bringing its total land area to 22,620 hectares.

The Gochager Lake property is host to a historic resource defined by drilling in 1966-1967 consisting of 4.2 M tons grading 0.29% Ni and 0.08% Cu. Recent drilling by Fathom has defined multiple very robust off-hole borehole electromagnetic (BHEM) responses in eight of nine holes drilled in 2023 and three historic drill holes probed. There is very strong evidence of multiple, high-grade nickel-copper-cobalt steeply oriented chutes within the historic Gochager Lake Deposit.

Prior to Fathom exploration in 2023 and since 1970, exploration at the property has been limited to small drill programs in 1989-1990 and 2018. Exploration plans for 2024 include expanded surface geophysical programs, drilling and continued BHEM surveys to expand tons and increase the grade of the historic Gochager Lake deposit. Summer exploration will consist of soil geochemistry, mapping, prospecting and additional surface geophysical programs focused on identifying other Gochager-like deposits within the current land package.

Market Opportunity

Nickel plays a crucial role in clean energy technologies, and that is expected to cause demand to well outstrip supply for the foreseeable future.

With an annual market value of around $35 billion, nickel demand is projected to rise due to its intensive use in lithium-ion batteries used to power EVs. However, new discoveries of nickel sulfide deposits (currently the most reliable source for battery-grade class 1 nickel) have been rare, which could constrain class 1 nickel supply in the coming years.

According to Deloitte’s global EV forecast, total EV sales will grow from 2.5 million in 2020 to 11.2 million in 2025, reaching 31.1 million by 2030 and representing approximately 32% of the total market share for new car sales. Over the next 10 years, the EV market is projected to see a CAGR of 29%, with increased demand for nickel expected to be comparable.

Management Team

Fathom Nickel has assembled a best-in-class leadership team consisting of highly qualified industry professionals with deep knowledge and understanding of the mineral exploration industry and capital markets.

Ian Fraser, P.Geo., is CEO, VP Exploration and Co-Founder of Fathom Nickel. He has more than 35 years of experience in mineral exploration, as well as managing and implementing exploration projects in Canada and internationally. His experience includes resource interpretation and development of the Casa Berardi Gold Mine and Komis Gold Mine, as well as the Cisneros Gold Mine in Colombia.

Doug Porter, CPA, CA, CBV, is President, CFO and Director of Fathom Nickel. He is a senior financial and accounting executive with specific emphasis in resource company management. His career includes positions with Elan Coal Ltd., Altitude Resources Ltd. and StimWrx Oilfield Services Ltd.

Fathom Nickel Inc. (OTCQB: FNICF), closed Wednesday's trading session at $0.0332, even for the day, on 10,100 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0222/$0.2588.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates, today announced its receipt of three patents granted in the U.S., strengthening its patent portfolio. The issued patents include one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation. As of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use.

"We are pleased to announce these U.S. patent issuances which help increase the commercial value of our programs and ensure the long-term protection of our drug research and development efforts. We are committed to continuing to build our patent portfolio to protect our novel drug candidates, methods of manufacturing these drugs, how they are formulated and how they are used to support the development of new treatments for diseases with high unmet medical needs," said Eric A. Adams, InMed's President and CEO.

To view the full press release, visit https://ibn.fm/r84IM

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Wednesday's trading session at $0.42, off by 2.5974%, on 17,684,698 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1207/$2.08.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Natural killer cells are white blood cells that eliminate cancer or other infected cells in the human body. Now a new study has looked into these cells' ability to eliminate a certain type of cancer known as malignant rhabdoid tumor. This aggressive and rare type of brain cancer starts developing in a child's kidneys, soft tissues or other organs. It mainly affects young children and babies. In some instances, natural killer cells can be overpowered by the cancer cells. Scientists at Florida State University may have found a way to enhance natural killer cells that target this pediatric cancer. The research was led by Professor Qing-Xiang "Amy" Sang of the Department of Chemistry and Biochemistry at the institution. The study's coauthors included graduate researchers Drishty Badhon Sarker, Sonia Kiran and Yu Xue from the Department of Chemistry and Biochemistry in the College of Arts and Sciences; and Professor Yan Li of the Department of Chemical and Biomedical Engineering at the institution. The scientists published their findings in "Bioactive Materials." Other entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also exploring ways to bring better therapeutics targeting central nervous system cancers in both pediatric and adult patients. There is hope that all these efforts will yield paradigm shifts in the current clinical results obtained while treating cancer using existing options.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $0.166, off by 2.4677%, on 3,089,121 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0955/$6875.00.

Recent News

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Wednesday's trading session at $0.2996, up 49.7251%, on 200 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.05/$2.35.

Recent News

ECGI Holdings Inc. (OTC: ECGI)

The QualityStocks Daily Newsletter would like to spotlight ECGI Holdings Inc. (OTC: ECGI).

ECGI Holdings Inc. (OTC: ECGI) is a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion. The company owns and manages a five-acre vineyard in Lake County, California, specializing in cultivating the Petite Sirah varietal, known for its bold and rich character, aligning with the growing demand for unique and high-quality wine experiences.

In the fashion sector, ECGI has strategically invested in Pacific Saddlery, a premier manufacturer and retailer of luxury equestrian tack, apparel and accessories. This unique blend of wine and fashion investments reflects ECGI Holdings’ commitment to delivering sophistication and innovation across diverse markets, positioning the company as a distinctive player in the intersection of technology, viticulture and luxury lifestyle.

Moving forward, ECGI Holdings is focused on identifying and capitalizing on growth opportunities that align with the company’s business objectives and continuing to improve its financial structure. In 2024, ECGI Holdings was approved by Evolve — a distinguished name in vacation rental management. This partnership will transform the company’s 40-acre Lake County property into a luxurious short-term rental destination aptly named Vintner’s Caldera Ranch.

ECGI Holdings is excited about the possibilities that Vintner’s Caldera Ranch creates for shareholders and looks forward to further developments poised to unlock the value of other underutilized assets. The company believes that it is laying a solid foundation for sustained success and profitability in the years to come.

ECGI Holdings is headquartered in Irvine, California.

Operational Philosophy

ECGI Holdings has embarked on an ambitious new vision and strategic direction to build and nurture luxury brands that resonate with its core values and market aspirations. Its joint venture with Pacific Saddlery epitomizes ECGI Holdings’ strategic shift toward luxury branding, leveraging Pacific Saddlery’s tangible and established market presence in equestrian products.

This transition will also allow ECGI Holdings to explore new pathways to monetize its underutilized assets, including the company’s vineyard. A key highlight of the company’s future outlook is the debut of Pacific Saddlery’s new mobile retail boutique at specific equestrian events in 2024. This innovative venture represents a significant step in ECGI Holdings’ strategy to enhance brand visibility and engage directly with the company’s target market.

In addition, the Vintner’s Caldera Ranch development marks a significant step in advancing the company’s strategy to revitalize and leverage underutilized assets. Vintner’s Caldera Ranch is set against the backdrop of Lake County’s breathtaking scenery, offering an exclusive getaway experience that blends natural beauty with luxury. Choosing Evolve is a strategic move to ensure that Vintner’s Caldera Ranch not only meets but exceeds the high standards of service that luxury guests expect.

Evolve’s expertise in maximizing rental potential and delivering exceptional guest experiences is crucial to the company’s vision of making Vintner’s Caldera Ranch a preferred choice for discerning travelers. With this venture, ECGI Holdings is not only expanding its footprint within the luxury rental marketplace, but also contributing to the local economy and enhancing the appeal of Lake County as a tourist destination.

The company’s focus remains steadfast on strategic growth, operational excellence and customer satisfaction.

Market Outlook

A report from Grand View Research, a global market research and consulting company, estimated the value of the worldwide luxury brands market at $366.23 billion in 2023 and projects the market to grow to a value of $580.43 billion by 2030, achieving a CAGR of 6.8% over the forecast period.

Rising disposable income and wealth in various regions of the world, particularly in emerging markets such as China and India, have propelled the growth of the market, according to the report.

Younger consumers, such as millennials and Generation Z, are increasingly entering the luxury market, driving demand for more contemporary and experiential luxury offerings. The rise of social media and influencer marketing has greatly impacted the visibility and desirability of luxury products, the report states.

Management Team

Jamie Steigerwald is CEO of ECGI Holdings, Inc. He is a successful entrepreneur with over 30 years of experience. Most recently, he was COO of Sugarmade Inc. (OTC: SGMD), a California cannabis real estate, cultivation, manufacturing and services company. He is the owner of SwiftLead, an Orange County web marketing, design and development company. He previously was COO for First USA Home Loans, a retail mortgage lender, and co-founder and President of SwiftLead Software, a mortgage lead tracking system.

Nick Collins is CEO at Pacific Saddlery. He brings over 25 years of expertise in equestrian luxury goods. He previously founded Rolling Meadows and created the Allon Equestrian and Renard et Cheval apparel brands. He was instrumental in creating and launching Kaval.com, an online equestrian apparel and accessories site.

ECGI Holdings Inc. (OTC: ECGI), closed Wednesday's trading session at $0.0027, up 22.7273%, on 924,545 volume. The average volume for the last 3 months is 530,702 and the stock's 52-week low/high is $0.0016/$0.0149.

Recent News

GivBux Inc. (OTC: GBUX)

The QualityStocks Daily Newsletter would like to spotlightFathom GivBux Inc. (OTC: GBUX) .

GivBux Inc. (OTC: GBUX) is a publicly traded super app and charitable giving platform. The company is creating a sharing economic community of brands and consumers in which consumers have an easier and more convenient way to shop and buy, merchants have a more efficient and profitable way to advertise, and charities receive built-in contributions from the community’s transactions.

The GivBux Super App revolutionizes shopping by offering a user-friendly tool to make purchases swiftly at over 100 national retailers, along with an expanding roster of local merchants. Users earn cash back on every purchase, a portion of which can be directed toward a charity of their choice, embodying GivBux’s commitment to giving back. Additionally, the app is evolving to include numerous functionalities like social networking, e-commerce, banking, messaging, food delivery and transportation, following the super app model.

GivBux is forging a new path in charitable giving, with aspirations to build the largest community of givers in the United States, and eventually globally. The company believes it is uniquely positioned to make a major contribution to society by overlapping the worlds of commerce and philanthropy.

The GivBux Super App is currently available for free on the Google Play Store and the Apple App Store.

The company is headquartered in Newport Beach, California.

Products

The company, through wholly owned subsidiary GivBux Global Partners Inc., is engaged in the fintech mobile wallet sector, specifically as a point-of-sale payment system by means of a consumer mobile wallet. GivBux uses smartphone technology to bridge consumers and merchants together without the need for traditional plastic cards or paper cash.

The GivBux mobile app has been designed to store, send and receive funds; donate; and make real-time purchases at top retail brands, restaurants and other venues. The brands benefit, because they are empowered with a data-rich marketing tool to reach and retain consumers through their mobile phones.

With GivBux, recipients can use funds instantly by paying with their mobile phones at thousands of locations. GivBux rewards all users for using the app every time they make a purchase and every time their friends, friends of friends and stranger friends make purchases with the GivBux mobile wallet. These rewards can be redeemed for cash to pay at participating retail stores, restaurants, cinemas, entertainment venues and more.

Moreover, GivBux allows users to contribute to a charity or worthy cause of their choice. To encourage giving and recommendations, a trending ‘Top 10 List’ of all charities will be generated and displayed on the mobile wallet based on ongoing contributions by GivBux users.

Market Opportunity

A report from Future Market Insights, a New York-based market research organization, estimated the worldwide mobile wallet market at $9.5 billion in 2023. The report projects that in 2024 the industry is likely to reach a valuation of $11.9 billion, and, by 2034, the mobile wallet market is forecast to grow to a value of $138.5 billion, achieving a CAGR of 27.8% over the forecast period.

Key market growth drivers include payment convenience, transaction security and continuing technological innovation. The report points out that mobile wallet payments are widely accepted worldwide, fueled by a rise in digital transactions and a growing use of mobile phones for simple and effective payment options. Innovations like blockchain integration, contactless payments and artificial intelligence are improving functionality and user experience while staying ahead of rapidly evolving digital payment trends, according to the report.

Management Team

Umesh Singh is President and Director at GivBux. He is a Certified Professional Accountant (Canada) with more than 25 years of experience in accounting and finance. He began his career at PwC before joining Hayes Stuart Little & Company (now Grant Thornton), where he was Senior Accountant-Manager and later Partner. Prior to being named GivBux president, he was a member of the GivBux Advisory Board for more than three years.

Michael Arnkvarn is Vice President of International Business Development at GivBux. He has over 30 years of experience in management, sales and marketing. He managed several medium and large agribusiness and environmental businesses before founding Collagenna Skin Care Products, a natural health products and cosmetics company, in 2004. He has been CEO of multiple public small-cap companies and co-founder of a start-up cannabis company that eventually sold for more than $800 million.

GivBux Inc. (OTC: GBUX), closed Wednesday's trading session at $0.5, up 19.0193%, on 780 volume. The average volume for the last 3 months is 9,031 and the stock's 52-week low/high is $0.205/$1.94.

Recent News

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF)

The QualityStocks Daily Newsletter would like to spotlight Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF).

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF), along with its consolidated subsidiaries, is a Canadian oil and gas exploration and production company with operations primarily focused in the Republic of Türkiye.

Headquartered in Canada, the company owns 49% of the SASB natural gas field, which is producing critical domestic supply of natural gas during Europe’s ongoing energy shortages. It also holds a 19.6% (except three wells with 9.8%) ownership interest in the Cendere Oil Field and has a farm-in agreement to earn 50% interest in three oil exploration blocks in southeast Türkiye called Cudi-Gabar.

Trillion Energy utilizes state-of-the-art technology and ingenious practices to produce and distribute oil and natural gas while still maintaining a commitment to sustainable and responsible operations. Whether through the development of new projects or optimizing existing assets, the company continues to seek new and innovative ways to drive growth and value for its stakeholders.

Headquartered in Vancouver, British Columbia, Trillion Energy is led by seasoned professionals who collectively boast over a century of energy exploration and development experience.

Projects

SASB Gas Field

The SASB Gas Field is producing and delivering critical domestic supplies of natural gas as energy shortages grip Europe due to Russia’s invasion of Ukraine.

Located in the southwestern Black Sea, the SASB gas field consists of numerous conventional natural gas pools located in shallow water. The fields have produced over 43 billion cubic feet (BCF) since initial development in 2007 and continue to provide much needed energy to Türkiye and the EU. Total infrastructure to date, including production platforms, pipelines, initial wells and gas processing plant, cost in excess of $600 million.

Trillion Energy is redeveloping the field with a strategic planned program of approximately 17 wells which commenced in 2022. Phase B of the program, targeted for 2024/25, consists of the re-entry of five legacy wells to drill sidetrack development wells and one exploration stratigraphic well.

Cendere Oil Field

Trillion Energy’s Cendere oil field is a long-term, low decline, stable oil production field located in Türkiye. The company has a 19.6% interest in the field, except for three wells in which its interest is 9.8%.

Cash flow after operating costs from the field is $120,000 to $140,000 per month, with average current production netting the company 110-120 barrels of oil per day. Estimated remaining Cendere oil reserves total 1.5 million barrels (0.277 million barrels net Trillion Energy).

The gross value of Trillion Energy’s interest is estimated at $13.85 million (NPV10).

Cudi-Gabar

Trillion Energy’s 10-well oil exploration drilling program is occurring on three prospective oil blocks located in the prolific Cudi-Gabar oil province in southeast Türkiye. The total area of the three blocks is 374,325 acres.

Trillion Energy’s potential 50% working and revenue interest in the blocks is earned by paying 100% of the work program costs. The company will operate the exploration program.
During 2023/24, Trillion Energy will shoot 351 kilometers of 2D seismic (150 km already shot on the eastern block) and drill four wells. The remaining six wells will be paid 50% by Trillion and 50% by the company’s partner. The oil blocks are surrounded by more than 10 major oil discoveries, half of which are recent.

Market Opportunity

A January 2024 report by Emergen Research, a market research and consulting company, estimated the global natural gas market at $310.5 trillion in 2022 and projected the market will be worth $443.8 trillion by 2032, achieving a CAGR of 3.7% during the forecast period. Increasing global economic activity and rising electricity consumption are key factors driving revenue growth of the market, according to the report.

Trillion Energy reports strong demand for natural gas in Türkiye, which is the seventh-largest natural gas consuming country in the world. Türkiye currently imports 98% of the natural gas it consumes, with about 60% of those imports coming from Iran and Russia.

Management Team

Dr. Arthur Halleran is CEO and Director of Trillion Energy. He has a Ph.D. in Geology from the University of Calgary and 44 years of petroleum exploration and development experience. His international experience includes work in Canada, Colombia, Egypt, India, Guinea, Sierra Leone, Sudan, Suriname, Chile, Brazil, Bulgaria, Türkiye, Pakistan, Peru, Tunisia, Trinidad Tobago, Argentina, Ecuador and Guyana. Dr. Halleran has worked for Petro-Canada, Chevron, Rally Energy and United Hydrocarbon International Corp. In 2007, he founded Canacol Energy Ltd., now the largest natural gas producer in Colombia.

Al Thorsen is COO of Trillion Energy. He is responsible for production operations of the SASB gas field, as well as future drilling activities in Türkiye and abroad. Highlights of his career include Valeura Energy Inc. as operations manager in Türkiye; Journey Energy, leading a production team; Rio Alto Exploration as country manager and production manager; Zargon Oil and Gas as VP of Operations; Orleans Energy as VP of Operations; and Central Petroleum as COO. He holds a Bachelor of Science in Petroleum Engineering from Montana College of Mineral Science & Technology.

Trillion Energy International Inc. (OTCQB: TRLEF), closed Wednesday's trading session at $0.094, even for the day, on 13 volume. The average volume for the last 3 months is 116,905 and the stock's 52-week low/high is $0.0682/$1.1815.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.